



in Immune ResponsesThe regulated degradation of ubiquitin
(ub)-tagged proteins by the ubiquitin pro-
teasome system (UPS) represents amajor
pathway not only for the maintenance of
proteostasis, but also for supplying
peptides for MHC class I antigen presen-
tation. This immune function of the UPS
can be improved by the immunoprotea-
some (IP), an isoenzyme of the 26S
proteasome with altered and enhanced
peptide hydrolyzing activity (Figures 1A
and 1E) (Deol et al., 2007; Seifert et al.,
2010; Huber et al., 2012).
In their Matters Arising (Nathan et al.,
2013 [this issue of Cell]), Nathan et al.
questioned several results of our original
study regarding the role of IP in
preserving proteostasis upon interferon
(IFN)-induced oxidative stress (Seifert
et al., 2010). We showed that IFN-induced
radical production augments the forma-
tion of poly-ub-conjugated, oxidant-
damaged nascent proteins (defective
ribosomal products [DRiPs]). The forma-
tion of DRiPs is transiently higher than
their degradation rate, resulting in a tran-
sient accumulation of poly-ub-conjugates
(Figure 1B). In comparison to standard
proteasomes (SP), IPs eliminate DRiPs
more efficiently and thereby concomi-
tantly facilitate the MHC class I peptide
supply (Figures 1A and 1E).
Nathan et al. were not able to detect an
IFN-g-induced transient increase in poly-
ub-conjugates or the accumulation of
ub-rich aggregates in the absence of IP.
They also did not detect any effect of IP
deficiency on disease manifestation in
experimental autoimmune encephalomy-
elitis (EAE) or accelerated degradation of
poly-ub-conjugates by IP. The reasons
for the discrepancies are not discussed.
In the majority of their experiments,
Nathan et al. applied different protocols,
thereby limiting a direct comparison with
our results. They further did not address
oxidative stress in their experiments, and
in addition, a number of technical issues
arise.To visualize IFN-induced accumulation
of poly-ub-conjugates, which was also
observed by other groups, it is essential
to counteract deubiquitylation and
degradation. Moreover, the kinetics and
the increase in poly-ub-conjugate forma-
tion are strictly dependent on cell
viability, the latter being affected by
IFN-g-signaling-induced apoptosis (see
Figure 1C and Supplemental Informa-
tion). The notion that conflicting data pre-
sented by Nathan et al. could simply
reflect distinct experimental setups is re-
inforced by the fact that one of the coau-
thors had replicated our findings in our
laboratory when using our stimulation
and buffer conditions (Spinnenhirn,
2009).
The transient accumulation of ub-
conjugates is, in part, due to the increased
expression of UBE2L6 (Seifert et al.,
2010), which is known to conjugate
both ub and the ub-like modifier ISG15
(Buchwald et al., 2010). Nathan et al.
argue that IFN-g-induced UBE2L6 is
preferentially involved in ISG15 modifica-
tion; however, they fail to detect IFN-g-
induced ISG15 conjugates. Our IFN
response experiments (Figure 1D) clearly
demonstrate that ISG15 protein conju-
gates do accumulate in response to IFN
but that ISGylation occurs much later
(24 hr) than ubiquitylation (8 hr).
Nathan et al. also claim that b5i/
LMP7/ mice are not more susceptible
to EAE than wild-type mice. However,
they used the abdominal area for
immunization, bearing the risk of severe
side effects, and, most strikingly, in-
vestigated mice from independent
colonies. Genetic differences in mouse
colonies and microbiotic environments
do affect the disease outcome in
EAE. Likewise, heterozygous breeding
needs to be performed to obtain related
wild-type littermates as optimal controls
in EAE studies (see Extended Experi-
mental Procedures in Supplemental
Information).Cell 152,In agreement with our data (Figure 1E),
Nathan et al. report an 2-fold higher
chymotrypsin-like peptide-hydrolyzing
activity of IP, which is due to b5i/LMP7-
induced structural changes. Of note,
Groettrup and coworkers (Huber et al.,
2012) cite our original study (Seifert
et al., 2010) to support their conclusion
that the b5i/LMP7 active sites are more
accessible to substrates. Unexpectedly,
Nathan et al. did not observe the 2-fold
enhanced poly-ub-substrate turnover
capacity of IP. In our in vitro degradation
experiments, we used saturating sub-
strate concentrations, thereby overruling
the effects of substrate affinity, and
visualized substrate turnover by immuno-
blotting. Nathan et al. used a substrate
concentration (30 nM) far below their
proposed Km values (140 and 180 nM),
which does not allow the determination
of differences in Vmax values between
SP and IP. Importantly, from their
supplemental data, it is obvious that, in
comparison to SP, 2-fold less IP were
applied for the in vitro degradation
experiments.
Based on different experimental
setups, including pulse-chase experi-
ments, the turnover rate of IkB-a, and
two mouse models of inflammation,
we showed that IP are more efficient
than SP in degrading poly-ub-conjugates
(Seifert et al., 2010). In contrast, the
data by Nathan et al. substantially limit
a conclusion regarding the ability
of IP to clear IFN-challenged cells
from the accumulation of ub-rich inclu-
sions because data on later time
points in their time course are missing.
The high poly-ub-substrate degrada-
tion capacity of IPs is important to
prevent disease progression (Seifert
et al., 2010). In support, pathological
consequences due to IP functional
impairment were meanwhile reported
by a number of other groups (Agarwal
et al., 2010; Arima et al., 2011; Hussong
et al., 2011; Kitamura et al., 2011;
Liu et al., 2012; Opitz et al., 2011; Zaiss
et al., 2011).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended
Experimental Procedures and can be found with
this article online at http://dx.doi.org/10.1016/




Figure 1. IFN-g Signaling Results in Transient Accumulation of Poly-Ub-Conjugates by
a Concerted Action of UPS Components followed by Increased Degradation Capacity of IP
(A) Total amounts of loadedMHC class I molecules at the cell surface correspondwith UPS activity in cells.
MHC class I molecules at the cell surface were measured by flow cytometry and staining with HLA-ABC
antibodies (BD). Treatment of human HeLa cells with 100 U/ml human IFN-g for 24 hr increased the MHC
class I surface expression 2-fold by increased peptide loading due to i26S proteasome peptide pro-
cessing. Depletion of the ub adaptor protein Rpn10 of the i26S proteasome by siRNA resulted in
a significant decrease of MHC class I surface expression in comparison to cells transfected with off-target
siRNA.
(B) MEFs derived from C57BL/6 mice displayed a transient accumulation of poly-ub-conjugates in
response to IFN-g (100 U/ml) for the indicated time points, as shown by immunoblot using a ub antibody
(DAKO). GAPDH served as loading control.
(C) Tunel assay of murine embryonic cardiomyocytes isolated from wild-type and b5i/LMP7/ mice in
response to IFN-g (100 U/ml) at the indicated time points showed increased cell death in IP-deficient cells.
Apoptosis in wild-type cardiomyocytes was observed at 96 hr IFN treatment and in b5i/LMP7/
cardiomyocytes at 48 hr. All cells were grown on cover slides for 96 hr. Cells were stained using in situ cell
death detection kit TMR red (Roche). Positive control: +DNAse (Roche) 400 U/ml; negative control: without
terminal deoxynucleotidyl transferase (TdT).
(D) IFN-g-mediated accumulation of ISG15 conjugates. Lysates of HeLa cells treated with IFN-a, IFN-b,
and IFN-g for the indicated time points were stained for ISG15 conjugates in immunoblots (ISG15-specific
antibody laboratory stock; GAPDH loading control).
(E) Native PAGE substrate overlay (Suc-LLVY-AMC) of total lysates of MEFs untreated or in response to
IFN-g for 48 hr showed an 2-fold increased chymotrypsin-like activity of IP (IFN-g) compared to SP
(untreated) (left). Native PAGE immunoblot stained IPs using LMP7-specific antibodies (laboratory stock)
(right). The migration of different proteasome complexes is indicated; amido black (AB) stain of the blot as
loading control (bottom).
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